PROCUREMENT PLAN (Textual Part)

Project information: Egypt Transforming Egypt's Healthcare System Project P167000

Project Implementation agency: Ministry of Health and Population

Date of the Procurement Plan: October 23, 2018

Period covered by this Procurement Plan: 18 months

Preamble

In accordance with paragraph 5.9 of the “World Bank Procurement Regulations for IPF Borrowers” (July 2016) (“Procurement Regulations”) the Bank’s Systematic Tracking and Exchanges in Procurement (STEP) system will be used to prepare, clear and update Procurement Plans and conduct all procurement transactions for the Project.

This textual part along with the Procurement Plan tables in STEP constitute the Procurement Plan for the Project. The following conditions apply to all procurement activities in the Procurement Plan. The other elements of the Procurement Plan as required under paragraph 4.4 of the Procurement Regulations are set forth in STEP.

The Bank’s Standard Procurement Documents: shall be used for all contracts subject to international competitive procurement and those contracts as specified in the Procurement Plan tables in STEP.

National Procurement Arrangements: In accordance with paragraph 5.3 of the Procurement Regulations, when approaching the national market (as specified in the Procurement Plan tables in STEP), the country’s own procurement procedures may be used.

Leased Assets: “Not Applicable”

Procurement of Second Hand Goods: “Not Applicable”

Domestic preference as specified under paragraph 5.51 of the Procurement Regulations (Goods and Works).

Goods: is applicable for those contracts identified in the Procurement Plan tables;

Other Relevant Procurement Information.

NA
<table>
<thead>
<tr>
<th>No.</th>
<th>Date</th>
<th>Description</th>
<th>Amount (US$)</th>
<th>Signed</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2018-12-16</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>2018-10-23</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>2018-11-28</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>2019-01-05</td>
<td>-</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Signed by:

- 28.09.06
- 2018-11-05
- 2019-01-05
<table>
<thead>
<tr>
<th>Item Code</th>
<th>Description</th>
<th>Quantity</th>
<th>Unit</th>
<th>Total</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG-MOHP-83223-GO-RFQ</td>
<td>Daclatasvir</td>
<td>400mg+</td>
<td>60</td>
<td>98,363.09</td>
<td>Signed 2018-10-28</td>
</tr>
<tr>
<td>EG-MOHP-83218-GO-RFQ</td>
<td>Daclatasvir</td>
<td>400mg+</td>
<td>60</td>
<td>98,363.09</td>
<td>Signed 2018-10-28</td>
</tr>
<tr>
<td>EG-MOHP-83217-GO-RFQ</td>
<td>Daclatasvir</td>
<td>400mg+</td>
<td>60</td>
<td>98,363.09</td>
<td>Signed 2018-10-28</td>
</tr>
<tr>
<td>EG-MOHP-83214-GO-RFQ</td>
<td>Daclatasvir</td>
<td>400mg+</td>
<td>60</td>
<td>98,363.09</td>
<td>Signed 2018-10-28</td>
</tr>
<tr>
<td>EG-MOHP-83217-GO-RFQ</td>
<td>Daclatasvir</td>
<td>400mg+</td>
<td>60</td>
<td>98,363.09</td>
<td>Signed 2018-10-28</td>
</tr>
<tr>
<td>EG-MOHP-83223-GO-RFQ</td>
<td>Daclatasvir</td>
<td>400mg+</td>
<td>60</td>
<td>98,363.09</td>
<td>Signed 2018-10-28</td>
</tr>
<tr>
<td>No.</td>
<td>Request Type</td>
<td>Quotations Requested</td>
<td>Quotations Received</td>
<td>Supplier Name</td>
<td>Purchase Quantity</td>
</tr>
<tr>
<td>-----</td>
<td>--------------</td>
<td>----------------------</td>
<td>--------------------</td>
<td>---------------</td>
<td>------------------</td>
</tr>
<tr>
<td>1</td>
<td>Multi</td>
<td>1</td>
<td>1</td>
<td>Almarj</td>
<td>100,484.91</td>
</tr>
<tr>
<td>2</td>
<td>Single</td>
<td>1</td>
<td>1</td>
<td>Alwayli</td>
<td>100,355.58</td>
</tr>
<tr>
<td>3</td>
<td>Single</td>
<td>1</td>
<td>1</td>
<td>Almarj</td>
<td>100,214.60</td>
</tr>
<tr>
<td>4</td>
<td>Single</td>
<td>1</td>
<td>1</td>
<td>Almarj</td>
<td>100,312.11</td>
</tr>
<tr>
<td>5</td>
<td>Single</td>
<td>1</td>
<td>1</td>
<td>Almarj</td>
<td>100,312.11</td>
</tr>
<tr>
<td>6</td>
<td>Single</td>
<td>1</td>
<td>1</td>
<td>Almarj</td>
<td>100,312.11</td>
</tr>
<tr>
<td>7</td>
<td>Single</td>
<td>1</td>
<td>1</td>
<td>Almarj</td>
<td>100,312.11</td>
</tr>
<tr>
<td>8</td>
<td>Single</td>
<td>1</td>
<td>1</td>
<td>Almarj</td>
<td>100,312.11</td>
</tr>
<tr>
<td>9</td>
<td>Single</td>
<td>1</td>
<td>1</td>
<td>Almarj</td>
<td>100,312.11</td>
</tr>
<tr>
<td>10</td>
<td>Single</td>
<td>1</td>
<td>1</td>
<td>Almarj</td>
<td>100,312.11</td>
</tr>
</tbody>
</table>

**Note:**
- The table above shows the distribution of requests, quotations received, and the corresponding quantities of purchased medicines.
- Each row indicates a specific request with the number of quotations both requested and received, the supplier name, and the purchase quantity.
<table>
<thead>
<tr>
<th>ENVELOPE</th>
<th>QUOTATIONS</th>
<th>REQUEST</th>
<th>POST</th>
<th>Level</th>
<th>Strengthening of the Health Sector</th>
<th>Date</th>
<th>Value</th>
<th>Signed</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>Egypt</td>
</tr>
</tbody>
</table>
400mg+ combination treatment / 400mg+ combination treatment of medicines for treatment of hepatitis.

Egyptian medicines for 400mg+ combination treatment of hepatitis.

EG-MOHP-83804-GO-RFQ
EG-MOHP-83803-GO-RFQ
EG-MOHP-83790-GO-RFQ
EG-MOHP-83775-GO-RFQ

Purchasing currently for 12 weeks for Daclatasvir 60 mg.

Program for 60 mg in the district.

C Quotations for Limited Stage - Post Envelope - 101,422.84
C Quotations for Limited Stage - Post Envelope - 102,046.01
C Quotations for Limited Stage - Post Envelope - 101,848.63
C Quotations for Limited Stage - Post Envelope - 101,609.72
C Quotations for Limited Stage - Post Envelope - 101,722.68

C Quotations for Limited Stage - Post Envelope - 99,386.73
C Quotations for Limited Stage - Post Envelope - 99,158.81
C Quotations for Limited Stage - Post Envelope - 99,124.11

C Quotations for Limited Stage - Post Envelope - 0.00
C Quotations for Limited Stage - Post Envelope - 0.00
C Quotations for Limited Stage - Post Envelope - 0.00
C Quotations for Limited Stage - Post Envelope - 0.00
C Quotations for Limited Stage - Post Envelope - 0.00

Signed Implement Pending 2018-12-03
Signed Implement Pending 2018-11-25
Signed Implement Pending 2018-11-25
Signed Implement Pending 2018-11-25
Signed Implement Pending 2018-11-25

Signed Implement Pending 2019-02-13
Signed Implement Pending 2019-01-24
Signed Implement Pending 2019-01-24
Signed Implement Pending 2019-01-24
Signed Implement Pending 2019-01-24

<table>
<thead>
<tr>
<th>Item</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Daclatasvir for 400mg+ 60 days</td>
</tr>
<tr>
<td>2.</td>
<td>Daclatasvir for 400mg+ 12 days</td>
</tr>
<tr>
<td>3.</td>
<td>Daclatasvir for 400mg+ 88 days</td>
</tr>
<tr>
<td>4.</td>
<td>Daclatasvir for 400mg+ 30 days</td>
</tr>
<tr>
<td>5.</td>
<td>Daclatasvir for 400mg+ 5 days</td>
</tr>
<tr>
<td>6.</td>
<td>Daclatasvir for 400mg+ 31 days</td>
</tr>
<tr>
<td>7.</td>
<td>Daclatasvir for 400mg+ 9 days</td>
</tr>
<tr>
<td>8.</td>
<td>Daclatasvir for 400mg+ 7 days</td>
</tr>
<tr>
<td>9.</td>
<td>Daclatasvir for 400mg+ 4 days</td>
</tr>
<tr>
<td>10.</td>
<td>Daclatasvir for 400mg+ 2 days</td>
</tr>
</tbody>
</table>

**Specifications**

- Daclatasvir 400mg+:
  - Daily dosage: 600mg
  - Duration: 12 weeks

**Quotations**

- Quotation ID: EG-MOHP-92454-GO-RFQ
- Quotation Date: 2018-12-20
- Amount: 105,618.87

- Quotation ID: EG-MOHP-92441-GO-RFQ
- Quotation Date: 2018-12-20
- Amount: 105,086.91

- Quotation ID: EG-MOHP-92437-GO-RFQ
- Quotation Date: 2018-12-20
- Amount: 105,909.36

- Quotation ID: EG-MOHP-88971-GO-RFQ
- Quotation Date: 2018-12-20
- Amount: 106,732.07

**Signatures**

- Healthcare Level: Single Envelope Stage 105,618.87
- Healthcare Level: Single Envelope Stage 105,086.91
- Healthcare Level: Single Envelope Stage 105,909.36
- Healthcare Level: Single Envelope Stage 106,732.07

**Comments**


**Notes**

- Please review the above details for Daclatasvir 400mg+ treatment.
<table>
<thead>
<tr>
<th>Code</th>
<th>Details</th>
<th>TAHTA</th>
<th>Cost (EGP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG-MOHP-92477</td>
<td>DACLATASVIR &amp; SOFOSBVIR</td>
<td>60</td>
<td>105,263.79</td>
</tr>
<tr>
<td>EG-MOHP-92477</td>
<td>DACLATASVIR &amp; SOFOSBVIR</td>
<td>60</td>
<td>105,231.99</td>
</tr>
<tr>
<td>EG-MOHP-92477</td>
<td>DACLATASVIR &amp; SOFOSBVIR</td>
<td>60</td>
<td>105,283.47</td>
</tr>
<tr>
<td>EG-MOHP-92477</td>
<td>DACLATASVIR &amp; SOFOSBVIR</td>
<td>60</td>
<td>105,554.04</td>
</tr>
<tr>
<td>EG-MOHP-92477</td>
<td>DACLATASVIR &amp; SOFOSBVIR</td>
<td>60</td>
<td>105,715.59</td>
</tr>
<tr>
<td>EG-MOHP-92477</td>
<td>DACLATASVIR &amp; SOFOSBVIR</td>
<td>60</td>
<td>0.00</td>
</tr>
</tbody>
</table>

The above table details the prices for different codes corresponding to the combination of DACLATASVIR and SOFOSBVIR within the TAHTA framework. The cost is given in Egyptian Pounds (EGP).
national insurance for weeks
Sofosbuvir and Daclatasvir are currently used for the treatment of the Egyptian virus.

400mg+ 60mg 12mg
EG-MOHP-92551-GO-RFQ
EG-MOHP-92548-GO-RFQ
EG-MOHP-92542-GO-RFQ
EG-MOHP-92537-GO-RFQ

Strengthen Level Healthcare Post Quotations Request Limited - 0.00 2018-12-29 2019-01-08 2019-03-07
Signed 88950 450-42 400-04 20 20 20 06 12

International Bank for Reconstruction and Development (IBRD)
<table>
<thead>
<tr>
<th>EG-MOHP-92574-GO-RFQ</th>
<th>105,989.41</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG-MOHP-92573-GO-RFQ</td>
<td>105,263.79</td>
</tr>
<tr>
<td>EG-MOHP-92572-GO-RFQ</td>
<td>106,295.91</td>
</tr>
<tr>
<td>EG-MOHP-92570-GO-RFQ</td>
<td>106,054.11</td>
</tr>
<tr>
<td>EG-MOHP-92564-GO-RFQ</td>
<td>105,957.39</td>
</tr>
<tr>
<td>EG-MOHP-92558-GO-RFQ</td>
<td>105,522.15</td>
</tr>
<tr>
<td>EG-MOHP-92560-GO-RFQ</td>
<td>104,674.47</td>
</tr>
<tr>
<td>EG-MOHP-92559-GO-RFQ</td>
<td>105,425.43</td>
</tr>
<tr>
<td>EG-MOHP-92555-GO-RFQ</td>
<td>105,425.43</td>
</tr>
<tr>
<td>EG-MOHP-92550-GO-RFQ</td>
<td>54,260.24</td>
</tr>
</tbody>
</table>

Table shows the prices for different products.
<table>
<thead>
<tr>
<th>Date</th>
<th>Quantity</th>
<th>Unit</th>
<th>Price</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-12-29</td>
<td></td>
<td></td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>2018-01-06</td>
<td></td>
<td></td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>2019-03-07</td>
<td></td>
<td></td>
<td>0.00</td>
<td>0.00</td>
</tr>
</tbody>
</table>

**Note:**
- All values are in the currency unit of the respective date.
<table>
<thead>
<tr>
<th>Code</th>
<th>Name</th>
<th>Type</th>
<th>Quantity</th>
<th>Unit</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG-MOHP-99007-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-99003-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>107,209.89</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-98997-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-93913-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,892.66</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-93904-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-93901-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92616-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92615-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92614-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92613-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92612-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92611-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92610-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92609-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92608-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92607-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92606-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92605-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92604-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92603-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92602-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92601-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92600-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92600-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92600-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92600-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92600-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92600-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92600-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92600-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92600-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92600-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92600-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92600-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92600-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92600-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-92600-GO-RFQ</td>
<td>Currently are national/treatment/are through Egyptian district. to weeks Sofosbuvir national to planning/contraceptives Suweif contraceptives/Daclatasvir the for weeks Sofosbuvir for national Treatment/EG-MOHP-92600-GO-RFQ</td>
<td>Purchasing</td>
<td>400mg+ 60 12 mg</td>
<td>105,835.91</td>
<td></td>
</tr>
</tbody>
</table>
weeks

Daclatasvir

to

Sofosbuvir
to

Daclatasvir

Sofosbuvir

to

to

to

Daclatasvir

Daclatasvir

Sofosbuvir

Sofosbuvir

EG-MOHP-99268-GO-RFQ

EG-MOHP-99271-GO-RFQ

EG-MOHP-99039-GO-RFQ

Ras
district.

Purchasing

Purchasing

Purchasing

Purchasing

400mg+

400mg+

400mg+

400mg+

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C
Sofosbuvir are national drugs RFQ 400 combination Governorate drugs RFQ weeks. Sofosbuvir are through currently Qena weeks Daclatasvir Sofosbuvir through currently Qena weeks through the RFQ Sofosbuvir national Qena drugs RFQ treatment through Daclatasvir national to Daclatasvir combination Purchasing Sant El Damnhour 12 weeks Egyptian for Qena for combination purchasing the treatment viruses of Egyptian district. Egyptian district of Egyptian bus for district for district the buses IBRD Medium for IBRD Healthcare for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBRD for IBR...
<table>
<thead>
<tr>
<th>Governorate</th>
<th>Daclatasvir (mg)</th>
<th>Sofosbuvir (mg)</th>
<th>Combination (mg)</th>
<th>Q1 Quantity</th>
<th>Q1 Value (EGP)</th>
<th>Q2 Quantity</th>
<th>Q2 Value (EGP)</th>
<th>Q3 Quantity</th>
<th>Q3 Value (EGP)</th>
<th>Q4 Quantity</th>
<th>Q4 Value (EGP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giza</td>
<td>60</td>
<td>400</td>
<td>460</td>
<td>1,086,380</td>
<td>105,879.51</td>
<td>1,057,831</td>
<td>105,559.56</td>
<td>105,222.62</td>
<td>104,693.14</td>
<td>105,752.10</td>
<td>105,896.51</td>
</tr>
<tr>
<td>Cairo</td>
<td>60</td>
<td>400</td>
<td>460</td>
<td>1,086,380</td>
<td>105,879.51</td>
<td>1,057,831</td>
<td>105,559.56</td>
<td>105,222.62</td>
<td>104,693.14</td>
<td>105,752.10</td>
<td>105,896.51</td>
</tr>
<tr>
<td>Alexandria</td>
<td>60</td>
<td>400</td>
<td>460</td>
<td>1,086,380</td>
<td>105,879.51</td>
<td>1,057,831</td>
<td>105,559.56</td>
<td>105,222.62</td>
<td>104,693.14</td>
<td>105,752.10</td>
<td>105,896.51</td>
</tr>
<tr>
<td>Elminya</td>
<td>60</td>
<td>400</td>
<td>460</td>
<td>1,086,380</td>
<td>105,879.51</td>
<td>1,057,831</td>
<td>105,559.56</td>
<td>105,222.62</td>
<td>104,693.14</td>
<td>105,752.10</td>
<td>105,896.51</td>
</tr>
</tbody>
</table>
Daclatasvir and Sofosbuvir are currently used for the treatment of HCV infection in several Egyptian Governorates. The combination of Daclatasvir and Sofosbuvir is recommended for the treatment of HCV infection in Egypt, and the drugs are procured through the IBRD/88950 Request for Quotations (RFQ) process. The following table provides the details of the procurement:

<table>
<thead>
<tr>
<th>Governorate</th>
<th>Drug Combination</th>
<th>Quantity</th>
<th>Unit</th>
<th>Cost (Egyptian Pounds)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dakhlya</td>
<td>Daclatasvir</td>
<td>12 weeks</td>
<td></td>
<td>105,752.10</td>
</tr>
<tr>
<td>Giza</td>
<td>Daclatasvir</td>
<td>12 weeks</td>
<td></td>
<td>105,463.29</td>
</tr>
<tr>
<td>Manzla</td>
<td>Daclatasvir</td>
<td>12 weeks</td>
<td></td>
<td>106,425.99</td>
</tr>
<tr>
<td>Matria</td>
<td>Daclatasvir</td>
<td>12 weeks</td>
<td></td>
<td>109,072.93</td>
</tr>
</tbody>
</table>

The above table represents the procurement of Daclatasvir and Sofosbuvir in the specified Governorates. The quantities are specified in weeks, and the cost is in Egyptian Pounds. The procurement process is conducted through the IBRD/88950 RFQ.
combination treatment

district

weeks

Daclatasvir
Sofosbuvir are currently

RFQ

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg

400 Egyptian

used

mg
<table>
<thead>
<tr>
<th></th>
<th>Quotations Requested</th>
<th>Quotations Received</th>
<th>RFQ Issued</th>
<th>MOHP-115197</th>
</tr>
</thead>
</table>

**Notes:**
- Daclatasvir/SofoSuvir combination for treatment of chronic hepatitis C virus (HCV) infection in adults is used currently.
- 28 weeks of treatment is used in national program.
- IBRD/IDA: $88950 0.00
- Implement Stage 1 Level Healthcare Strengthening Activities (C) - 106,199.39
- Implement Stage 2 Level Healthcare Strengthening Activities (C) - 106,441.09
- Implement Stage 3 Level Healthcare Strengthening Activities (C) - 106,972.81
- Implement Stage 4 Level Healthcare Strengthening Activities (C) - 108,000.00
- Pending Stage 1 Level Healthcare Strengthening Activities (C) - 106,199.39
- Pending Stage 2 Level Healthcare Strengthening Activities (C) - 106,441.09
- Pending Stage 3 Level Healthcare Strengthening Activities (C) - 106,972.81
- Pending Stage 4 Level Healthcare Strengthening Activities (C) - 108,000.00
- Under Stage 1 Level Healthcare Strengthening Activities (C) - 106,199.39
- Under Stage 2 Level Healthcare Strengthening Activities (C) - 106,441.09
- Under Stage 3 Level Healthcare Strengthening Activities (C) - 106,972.81
- Under Stage 4 Level Healthcare Strengthening Activities (C) - 108,000.00

**Eligibility:**
- One single envelope quote is requested for each district.
- Program Quotations Requested are used for Districts.
- Program Quotations Received are used for Districts.
<table>
<thead>
<tr>
<th>No.</th>
<th>Medication</th>
<th>Brand</th>
<th>Grade</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Daclatasvir</td>
<td>Ras</td>
<td>60 mg</td>
<td>106,594.30</td>
<td>106,634.44</td>
</tr>
<tr>
<td>2</td>
<td>Sofosbuvir</td>
<td>El</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>3</td>
<td>Sofosbuvir</td>
<td>IBRD</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>4</td>
<td>Daclatasvir</td>
<td>Shrq</td>
<td>60 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>5</td>
<td>Daclatasvir</td>
<td>IBRD</td>
<td>60 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>6</td>
<td>Sofosbuvir</td>
<td>Shrq</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>7</td>
<td>Sofosbuvir</td>
<td>IBRD</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>8</td>
<td>Daclatasvir</td>
<td>Shrq</td>
<td>60 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>9</td>
<td>Daclatasvir</td>
<td>IBRD</td>
<td>60 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>10</td>
<td>Sofosbuvir</td>
<td>Shrq</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>11</td>
<td>Sofosbuvir</td>
<td>IBRD</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>12</td>
<td>Daclatasvir</td>
<td>Shrq</td>
<td>60 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>13</td>
<td>Daclatasvir</td>
<td>IBRD</td>
<td>60 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>14</td>
<td>Sofosbuvir</td>
<td>Shrq</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>15</td>
<td>Sofosbuvir</td>
<td>IBRD</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>16</td>
<td>Daclatasvir</td>
<td>Shrq</td>
<td>60 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>17</td>
<td>Daclatasvir</td>
<td>IBRD</td>
<td>60 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>18</td>
<td>Sofosbuvir</td>
<td>Shrq</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>19</td>
<td>Sofosbuvir</td>
<td>IBRD</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>20</td>
<td>Daclatasvir</td>
<td>Shrq</td>
<td>60 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>21</td>
<td>Daclatasvir</td>
<td>IBRD</td>
<td>60 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>22</td>
<td>Sofosbuvir</td>
<td>Shrq</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>23</td>
<td>Sofosbuvir</td>
<td>IBRD</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>24</td>
<td>Daclatasvir</td>
<td>Shrq</td>
<td>60 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>25</td>
<td>Daclatasvir</td>
<td>IBRD</td>
<td>60 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>26</td>
<td>Sofosbuvir</td>
<td>Shrq</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>27</td>
<td>Sofosbuvir</td>
<td>IBRD</td>
<td>400 mg</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>No.</td>
<td>Item Description</td>
<td>Quantity</td>
<td>Unit</td>
<td>Price</td>
<td>Total</td>
</tr>
<tr>
<td>-----</td>
<td>--------------------------------</td>
<td>----------</td>
<td>------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td>1</td>
<td>Daclatasvir</td>
<td>12</td>
<td>kg</td>
<td>88950</td>
<td>107,828.22</td>
</tr>
<tr>
<td>2</td>
<td>Sofosbuvir</td>
<td>12</td>
<td>kg</td>
<td>88950</td>
<td>107,828.22</td>
</tr>
<tr>
<td>3</td>
<td>Faysal</td>
<td>12</td>
<td>kg</td>
<td>88950</td>
<td>107,828.22</td>
</tr>
<tr>
<td>4</td>
<td>Juhayna</td>
<td>12</td>
<td>kg</td>
<td>88950</td>
<td>107,828.22</td>
</tr>
<tr>
<td>5</td>
<td>Alsayidat</td>
<td>12</td>
<td>kg</td>
<td>88950</td>
<td>107,828.22</td>
</tr>
</tbody>
</table>

*Note: The prices are in Egyptian pounds and the quantities are in kilograms.*
<table>
<thead>
<tr>
<th>Country</th>
<th>Region</th>
<th>Product</th>
<th>Quotation ID</th>
<th>Quantity</th>
<th>Price</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Egypt</td>
<td>Cairo</td>
<td>Daclatasvir 60mg</td>
<td>EG-MOHP-115701-GO-001</td>
<td>100,000</td>
<td>100,000</td>
<td>10,000,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sofosbuvir 400mg+</td>
<td>EG-MOHP-115702-GO-001</td>
<td>100,000</td>
<td>100,000</td>
<td>10,000,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daclatasvir 60mg</td>
<td>EG-MOHP-115703-GO-001</td>
<td>100,000</td>
<td>100,000</td>
<td>10,000,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sofosbuvir 400mg+</td>
<td>EG-MOHP-115704-GO-001</td>
<td>100,000</td>
<td>100,000</td>
<td>10,000,000</td>
</tr>
</tbody>
</table>

**Notes:**
- All quotations are for a period of 12 weeks.
- All quantities are in mg.
- All prices are in US dollars.

**Signatories:**
- Ministry of Health
- Purchasing Board
- National Hepatitis Program
<table>
<thead>
<tr>
<th>Item Code</th>
<th>Country</th>
<th>Quantity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG-MOHP-123296-GO-002</td>
<td>Asyut</td>
<td>100</td>
<td>Tablet</td>
</tr>
<tr>
<td>EG-MOHP-123276-GO-002</td>
<td>Luxor</td>
<td>400</td>
<td>Tablet</td>
</tr>
<tr>
<td>EG-MOHP-123298-GO-002</td>
<td>Cairo</td>
<td>100</td>
<td>Tablet</td>
</tr>
</tbody>
</table>

**Notes:**
- Each item contains a fixed dose.
- For more details, please refer to the related projects and institutions.
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG-MOHP-143441-GO-</td>
<td>Drug</td>
<td>40</td>
</tr>
<tr>
<td>EG-MOHP-143432-GO-</td>
<td>Drug</td>
<td>12</td>
</tr>
<tr>
<td>EG-MOHP-143431-GO-</td>
<td>Drug</td>
<td>12</td>
</tr>
<tr>
<td>EG-MOHP-141779-GO-</td>
<td>Drug</td>
<td>12</td>
</tr>
<tr>
<td>EG-MOHP-141774-GO-</td>
<td>Drug</td>
<td>12</td>
</tr>
<tr>
<td>EG-MOHP-141756-GO-</td>
<td>Drug</td>
<td>12</td>
</tr>
<tr>
<td>EG-MOHP-140421-GO-</td>
<td>Drug</td>
<td>12</td>
</tr>
<tr>
<td>EG-MOHP-94071-GO-RFQ</td>
<td>Drug</td>
<td>12</td>
</tr>
</tbody>
</table>

**Intervention: Acute Care**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAY</td>
<td>Intubation</td>
<td>12</td>
</tr>
<tr>
<td>AHM</td>
<td>Rehabilitaion</td>
<td>12</td>
</tr>
<tr>
<td>RFB</td>
<td>Equipment</td>
<td>12</td>
</tr>
</tbody>
</table>

**Microbiology**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGM</td>
<td>Equipment</td>
<td>12</td>
</tr>
</tbody>
</table>

**Ophthalmology**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>RFB</td>
<td>Equipment</td>
<td>12</td>
</tr>
</tbody>
</table>

**Dental**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>RFB</td>
<td>Equipment</td>
<td>12</td>
</tr>
</tbody>
</table>

**Investigation**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>RFB</td>
<td>Equipment</td>
<td>12</td>
</tr>
<tr>
<td>No.</td>
<td>Number</td>
<td>Description</td>
</tr>
<tr>
<td>-----</td>
<td>--------</td>
<td>-------------</td>
</tr>
<tr>
<td>1</td>
<td>1,500,000.00</td>
<td>2019-11-13</td>
</tr>
</tbody>
</table>

**Notes:**
- **Actual:** Indicates the actual amount or date.
- **Pending:** Indicates pending approval or action.
- **Signed:** Indicates the signed date or document.
- **Type:** Indicates the type of document or process.
- **Method:** Indicates the selection method.
- **Account:** Indicates the account number or identifier.
- **Team:** Indicates the team or group responsible.

**Reference:** Comprehensive reference to work for IBRD, including project selection, consultant, and post-reviews.